Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.

Griesinger F, Pérol M, Girard N, Durand-Zaleski I, Zacharias S, Bosquet L, Jänicke M, Quantin X, Groth A, Fleitz A, Calleja A, Patel S, Lacoin L, Daumont MJ, Penrod JR, Carroll R, Waldenberger D, Reynaud D, Thomas M, Chouaid C.

Open source

DOI: 10.1016/j.lungcan.2022.08.001
Published: 2022-08-06
Container: Lung Cancer
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.lungcan.2022.08.001,
  title = {Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.},
  author = {Griesinger F and  Pérol M and  Girard N and  Durand-Zaleski I and  Zacharias S and  Bosquet L and  Jänicke M and  Quantin X and  Groth A and  Fleitz A and  Calleja A and  Patel S and  Lacoin L and  Daumont MJ and  Penrod JR and  Carroll R and  Waldenberger D and  Reynaud D and  Thomas M and  Chouaid C.},
  year = {2022},
  journal = {Lung Cancer},
  doi = {10.1016/j.lungcan.2022.08.001},
  url = {https://doi.org/10.1016/j.lungcan.2022.08.001}
}

RIS

TY  - JOUR
TI  - Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.
AU  - Griesinger F
AU  -  Pérol M
AU  -  Girard N
AU  -  Durand-Zaleski I
AU  -  Zacharias S
AU  -  Bosquet L
AU  -  Jänicke M
AU  -  Quantin X
AU  -  Groth A
AU  -  Fleitz A
AU  -  Calleja A
AU  -  Patel S
AU  -  Lacoin L
AU  -  Daumont MJ
AU  -  Penrod JR
AU  -  Carroll R
AU  -  Waldenberger D
AU  -  Reynaud D
AU  -  Thomas M
AU  -  Chouaid C.
PY  - 2022
JO  - Lung Cancer
DO  - 10.1016/j.lungcan.2022.08.001
UR  - https://doi.org/10.1016/j.lungcan.2022.08.001
ER  -

APA

F, G., M, P., N, G., I, D., S, Z., L, B., M, J., X, Q., A, G., A, F., A, C., S, P., L, L., MJ, D., JR, P., R, C., D, W., D, R., M, T., & C., C. (2022). Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.. Lung Cancer. https://doi.org/10.1016/j.lungcan.2022.08.001

Source records

europe-pmc · retrieved 2026-09-25T22:17:06.740Z
hal · retrieved 2026-09-25T22:17:06.777Z